WO2001068603A3 - Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use - Google Patents
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use Download PDFInfo
- Publication number
- WO2001068603A3 WO2001068603A3 PCT/US2001/007151 US0107151W WO0168603A3 WO 2001068603 A3 WO2001068603 A3 WO 2001068603A3 US 0107151 W US0107151 W US 0107151W WO 0168603 A3 WO0168603 A3 WO 0168603A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dipeptidyl
- cyclopropyl
- processes
- preparation
- based inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
Abstract
Priority Applications (40)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK01918383T DK1261586T3 (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl Condensed Dipeptidyl Peptidase IV Inhibitors Based on Pyrrolidine, Methods for their Preparation and Use |
HU0302792A HU228110B1 (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv and method for their preparation and pharmaceutical compositions containing the compounds |
MXPA02008837A MXPA02008837A (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl fused pyrrolidine based inhibitors of dipeptidyl peptidase iv and method. |
CA2402894A CA2402894C (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv and method |
KR1020067004515A KR100758407B1 (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
JP2001567699A JP4460205B2 (en) | 2000-03-10 | 2001-03-05 | Inhibitors and methods for dipeptidyl peptidase IV having a cyclopropyl-fused pyrrolidine skeleton |
DE122010000008C DE122010000008I1 (en) | 2000-03-10 | 2001-03-05 | CYCLOPROPYL-CONDENSED DIPEPTIDYL-PEPTIDASE IV HEMMER BASED ON PYRROLIDINE, PROCESS FOR THEIR PREPARATION AND THEIR USE |
PL365520A PL207041B1 (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
DE60134122T DE60134122D1 (en) | 2000-03-10 | 2001-03-05 | CYCLOPROPYL-CONDENSED DIPEPTIDYL-PEPTIDASE IV HEMMER BASED ON PYRROLIDINE, PROCESS FOR THEIR PREPARATION AND THEIR USE |
AU4546601A AU4546601A (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv and method |
HU1200546A HU230380B1 (en) | 2000-03-10 | 2001-03-05 | N-protected amino hydroxy adamantane carboxylic acid and process for producing the same |
ES01918383T ES2305062T3 (en) | 2000-03-10 | 2001-03-05 | INHIBITORS BASED ON PIROLIDINE CONDENSED WITH CYCLOPROPYL OF PIPEPTIDIL PEPTIDASE IV, PROCEDURES FOR THEIR PREPARATION, AND THEIR USE. |
NZ520821A NZ520821A (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, method ofr preparation, and their use |
BRPI0109115A BRPI0109115B8 (en) | 2000-03-10 | 2001-03-05 | fused cyclopropyl pyrrolidine-based dipeptidyl peptidase inhibitors iv and method |
CZ2015493A CZ307821B6 (en) | 2000-03-10 | 2001-03-05 | |
KR1020027011806A KR100754089B1 (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
HU1200545A HU230347B1 (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv, process for their preparation and their use |
EP01918383A EP1261586B1 (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv, processes for their preparation, and their use |
IL15137201A IL151372A0 (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine derivatives and pharmaceutical compositions containing the same |
EP15186007.9A EP2995615B1 (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv and their pharmaceutical use |
AU2001245466A AU2001245466B2 (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl IV, processes for their preparation, and their use |
IL151372A IL151372A (en) | 2000-03-10 | 2002-08-21 | Cyclopropyl-fused pyrrolidine derivatives and pharmaceutical compositions containing the same |
NO20024295A NO324227B1 (en) | 2000-03-10 | 2002-09-09 | Cyclopropyl-fused pyrrolidine-based compounds, pharmaceutical compositions and combinations containing them as well as the use thereof for the manufacture of medicaments for the treatment of diseases |
HK03101079.9A HK1049330B (en) | 2000-03-10 | 2003-02-14 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv, processes for their preparation, and their use |
IL177018A IL177018A0 (en) | 2000-03-10 | 2006-07-23 | Cyclopropyl-fused pyrrolidine derivatives and pharmaceutical compositions containing the same |
IL177019A IL177019A (en) | 2000-03-10 | 2006-07-23 | Protected amino hydroxyl adamantane carboxylic acid and methods for the preparation thereof |
CY20081100885T CY1108273T1 (en) | 2000-03-10 | 2008-08-20 | PYRROLIDINE-BASED INHIBITORS OF CYCLOPROPYL-FUSED DIPEPTYLPEPTIDASE 4 AND METHODS OF THEIR PREPARATION AND USE |
BE2010C008C BE2010C008I2 (en) | 2000-03-10 | 2010-02-11 | |
LU91650C LU91650I2 (en) | 2000-03-10 | 2010-02-17 | Saxagliptin and pharmaceutically acceptable salts thereof, including saxagliptin hydrochloride - Onglyza-saxagliptin |
NL300436C NL300436I1 (en) | 2000-03-10 | 2010-02-17 | Cyclopropyl-condensed pyrrolidine-based dipeptidyl peptidase IV inhibitors, methods for their preparation, and their use. |
FR10C0010C FR10C0010I2 (en) | 2000-03-10 | 2010-02-22 | DIPEPTIDYL-PEPTIDASE IV INHIBITORS COMPRISING A FUSED PYRROLIDINE AND CYCLOPROPYL, PROCESSES FOR THEIR PREPARATION AND USE OF THESE COMPOUNDS |
NO2010006C NO2010006I2 (en) | 2000-03-10 | 2010-03-16 | Saxagliptin and its pharmaceutically acceptable salts, including Saxagliptin hydrochloride |
CY2010005C CY2010005I1 (en) | 2000-03-10 | 2010-03-30 | PYRROLIDINE-BASED INHIBITORS OF CYCLOPROPYL-FUSED DIPEPTYLPEPTIDASE 4 AND METHODS OF THEIR PREPARATION AND USE |
BE2012C016C BE2012C016I2 (en) | 2000-03-10 | 2012-04-18 | |
DE201212000023 DE122012000023I1 (en) | 2000-03-10 | 2012-04-23 | Cyclopropyl-fused dipeptidyl-peptidase-IV inhibitors based on pyrrolidine, process for their preparation and their use. |
CY2012009C CY2012009I2 (en) | 2000-03-10 | 2012-04-24 | PYRROLIDINE-BASED INHIBITORS OF CYCLOPROPYL-FUSED DIPEPTYLPEPTIDASE 4 AND METHODS OF THEIR PREPARATION AND USE |
LU91985C LU91985I2 (en) | 2000-03-10 | 2012-04-25 | A combination product of Saxagliptin and metformin and pharmaceutically acceptable salts thereof, including the salts of Saxgliptin hydrochloride and metformin |
NO2012009C NO2012009I2 (en) | 2000-03-10 | 2012-05-21 | Combination product of saxaglipin and metformin and pharmaceutically acceptable salts thereof, including the HCI salts of saxaglipin and metformin |
HUS1200031C HUS1200031I1 (en) | 2000-03-10 | 2012-12-14 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv and method for their preparation and pharmaceutical compositions containing the compounds |
HUS1200030C HUS1200030I1 (en) | 2000-03-10 | 2012-12-14 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv and method for their preparation and pharmaceutical compositions containing the compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18855500P | 2000-03-10 | 2000-03-10 | |
US60/188,555 | 2000-03-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001068603A2 WO2001068603A2 (en) | 2001-09-20 |
WO2001068603A3 true WO2001068603A3 (en) | 2002-02-14 |
Family
ID=22693638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/007151 WO2001068603A2 (en) | 2000-03-10 | 2001-03-05 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
Country Status (37)
Country | Link |
---|---|
US (2) | US6395767B2 (en) |
EP (4) | EP2995615B1 (en) |
JP (5) | JP4460205B2 (en) |
KR (2) | KR100758407B1 (en) |
CN (2) | CN1213028C (en) |
AR (1) | AR027634A1 (en) |
AT (1) | ATE396176T1 (en) |
AU (2) | AU2001245466B2 (en) |
BE (2) | BE2010C008I2 (en) |
BR (1) | BRPI0109115B8 (en) |
CA (1) | CA2402894C (en) |
CO (1) | CO5280198A1 (en) |
CY (3) | CY1108273T1 (en) |
CZ (3) | CZ307821B6 (en) |
DE (3) | DE60134122D1 (en) |
DK (1) | DK1261586T3 (en) |
EG (1) | EG25854A (en) |
ES (4) | ES2768961T3 (en) |
FR (1) | FR10C0010I2 (en) |
HK (2) | HK1049330B (en) |
HU (5) | HU230380B1 (en) |
IL (4) | IL151372A0 (en) |
LU (2) | LU91650I2 (en) |
MX (1) | MXPA02008837A (en) |
MY (1) | MY124512A (en) |
NL (1) | NL300436I1 (en) |
NO (3) | NO324227B1 (en) |
NZ (1) | NZ520821A (en) |
PE (1) | PE20020771A1 (en) |
PL (1) | PL207041B1 (en) |
PT (1) | PT1261586E (en) |
RU (1) | RU2286986C2 (en) |
SG (1) | SG152030A1 (en) |
TW (2) | TW200624420A (en) |
UY (2) | UY26613A1 (en) |
WO (1) | WO2001068603A2 (en) |
ZA (1) | ZA200206816B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7897633B2 (en) | 2004-02-05 | 2011-03-01 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US8883714B2 (en) | 2008-04-07 | 2014-11-11 | Arena Pharmaceuticals, Inc. | Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues |
US8906901B2 (en) | 2005-09-14 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
US9150501B2 (en) | 2007-09-11 | 2015-10-06 | Gtx, Inc. | Solid forms of selective androgen receptor modulators |
US9321791B2 (en) | 2002-08-21 | 2016-04-26 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9415016B2 (en) | 2008-04-03 | 2016-08-16 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
Families Citing this family (299)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0487425A (en) * | 1990-07-31 | 1992-03-19 | Fujitsu Ltd | Circuit switching device |
US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
JP4300108B2 (en) * | 2001-06-27 | 2009-07-22 | スミスクライン ビーチャム コーポレーション | Pyrrolidines as dipeptidyl peptidase inhibitors |
US7183290B2 (en) * | 2001-06-27 | 2007-02-27 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
CA2450722A1 (en) * | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
EP1443919A4 (en) * | 2001-11-16 | 2006-03-22 | Bristol Myers Squibb Co | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
US7772433B2 (en) | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
US20040014681A1 (en) * | 2002-05-14 | 2004-01-22 | Ralph Ryback | Method for treating dermatoses and tissue damage |
US7405234B2 (en) * | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7378385B2 (en) * | 2002-08-08 | 2008-05-27 | University Of Cincinnati | Role for GLP-1 to mediate responses to disparate stressors |
US20040121964A1 (en) * | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US7238724B2 (en) * | 2002-09-19 | 2007-07-03 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US7262207B2 (en) | 2002-09-19 | 2007-08-28 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
EP1567487A4 (en) * | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | Open chain prolyl urea-related modulators of androgen receptor function |
US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US7420079B2 (en) * | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
US20060052382A1 (en) * | 2002-12-20 | 2006-03-09 | Duffy Joseph L | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
JP4887139B2 (en) * | 2003-03-25 | 2012-02-29 | 武田薬品工業株式会社 | Dipeptidyl peptidase inhibitor |
EP1620082B9 (en) | 2003-05-05 | 2010-08-25 | Probiodrug AG | Medical use of inhibitors of glutaminyl and glutamate cyclases for treating alzheimer's disease and down syndrome |
DE602004026289D1 (en) | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminyl INHIBITORS |
CN101837127A (en) | 2003-05-05 | 2010-09-22 | 前体生物药物股份公司 | The application of glutaminyl and glutamate cyclase effector |
JP2007511467A (en) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | Dipeptidyl peptidase inhibitor |
US7459474B2 (en) | 2003-06-11 | 2008-12-02 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
RU2006107553A (en) * | 2003-08-13 | 2007-09-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | 4-Pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
US7205409B2 (en) * | 2003-09-04 | 2007-04-17 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
EP1699777B1 (en) * | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20050065144A1 (en) * | 2003-09-08 | 2005-03-24 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
WO2005039548A2 (en) | 2003-10-15 | 2005-05-06 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
ZA200603165B (en) | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
WO2005047297A1 (en) * | 2003-11-12 | 2005-05-26 | Phenomix Corporation | Heterocyclic boronic acid compounds |
US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7317109B2 (en) * | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7767828B2 (en) * | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US20070149451A1 (en) * | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
KR20180050427A (en) | 2003-11-17 | 2018-05-14 | 노파르티스 아게 | Use of dipeptidyl peptidase iv inhibitors |
US7420059B2 (en) * | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
RS57561B1 (en) | 2004-01-20 | 2018-10-31 | Novartis Ag | Direct compression formulation and process |
US7470810B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Alkyl and aryl-thiotrifluoroacetates and process |
WO2005073186A1 (en) * | 2004-01-29 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | Pyrrolidine derivatives |
NZ548440A (en) * | 2004-02-05 | 2009-07-31 | Kyorin Seiyaku Kk | Bicycloester derivative inhibitng DPP-IV for treatment of diabetes or similar |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
KR20060129021A (en) * | 2004-02-18 | 2006-12-14 | 교린 세이야꾸 가부시키 가이샤 | Bicyclic amide derivatives |
EP1719757B1 (en) * | 2004-02-27 | 2013-10-09 | Kyorin Pharmaceutical Co., Ltd. | Bicyclo derivative |
US20070238753A1 (en) * | 2004-02-27 | 2007-10-11 | Madar David J | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
NZ549716A (en) * | 2004-03-15 | 2010-04-30 | Takeda Pharmaceutical | Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors |
TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
TW200538122A (en) | 2004-03-31 | 2005-12-01 | Bristol Myers Squibb Co | Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein |
US7741082B2 (en) * | 2004-04-14 | 2010-06-22 | Bristol-Myers Squibb Company | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor |
US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
US7829720B2 (en) | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
TW200536827A (en) * | 2004-05-04 | 2005-11-16 | Bristol Myers Squibb Co | Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors |
US7214702B2 (en) * | 2004-05-25 | 2007-05-08 | Bristol-Myers Squibb Company | Process for producing a dipeptidyl peptidase IV inhibitor |
TWI415635B (en) * | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | Coated tablet formulation and method |
WO2005118555A1 (en) * | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
ATE553077T1 (en) * | 2004-07-23 | 2012-04-15 | Nuada Llc | PEPTIDATE INHIBITORS |
TW200608967A (en) | 2004-07-29 | 2006-03-16 | Sankyo Co | Pharmaceutical compositions containing with diabetic agent |
US20060035954A1 (en) * | 2004-08-11 | 2006-02-16 | Sharma Padam N | Ammonolysis process for the preparation of intermediates for DPP IV inhibitors |
AR051446A1 (en) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2) |
DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
US7635699B2 (en) * | 2004-12-29 | 2009-12-22 | Bristol-Myers Squibb Company | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7589088B2 (en) * | 2004-12-29 | 2009-09-15 | Bristol-Myers Squibb Company | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
DOP2006000008A (en) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1 |
JP2008024592A (en) * | 2005-01-28 | 2008-02-07 | Taisho Pharmaceut Co Ltd | Cyanopyrrolidine derivative-containing composition for solid preparation, solid preparation containing the composition and process for producing the solid preparation |
US7238702B2 (en) * | 2005-02-10 | 2007-07-03 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5HT modulators |
JP2008115080A (en) * | 2005-04-22 | 2008-05-22 | Taisho Pharmaceutical Co Ltd | Combined pharmaceutical |
US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
US20060264433A1 (en) * | 2005-05-23 | 2006-11-23 | Backes Bradley J | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US7825139B2 (en) * | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
EP1910361A2 (en) * | 2005-07-28 | 2008-04-16 | Brystol-Myers Squibb Company | Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists |
DE102005035891A1 (en) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals |
TW200738245A (en) * | 2005-08-22 | 2007-10-16 | Sankyo Co | Pharmaceutical composition containing FBPase inhibitor |
US7795436B2 (en) * | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
JP2009506119A (en) | 2005-08-31 | 2009-02-12 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | Treatment of kidney disease, burns, wounds and spinal cord injury using selective androgen receptor modulators |
PE20070622A1 (en) * | 2005-09-14 | 2007-08-22 | Takeda Pharmaceutical | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS |
PE20070458A1 (en) * | 2005-09-14 | 2007-07-05 | Takeda Pharmaceutical | PHARMACEUTICAL COMPOSITION INCLUDING 2 - [[6- (3R) -3-AMINO-1-PIPERIDINYL] -3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1 (2H) -PYRIMIDINYL] METHYL] -BENZONITRILE AS A DIPEPTIDYL PEPTIDASE INHIBITOR |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
CN101360723A (en) * | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | Process for the preparation of pyrimidinedione derivatives |
TW200738266A (en) * | 2005-09-29 | 2007-10-16 | Sankyo Co | Pharmaceutical agent containing insulin resistance improving agent |
EP1943215A2 (en) | 2005-10-31 | 2008-07-16 | Brystol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
EP1971614A1 (en) | 2005-11-14 | 2008-09-24 | Probiodrug AG | Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors |
GB0526291D0 (en) * | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
CN101395131B (en) * | 2006-03-08 | 2012-11-14 | 杏林制药株式会社 | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof |
RU2465264C2 (en) * | 2006-03-16 | 2012-10-27 | Вертекс Фармасьютикалз Инкорпорейтед | Deuterated hepatitis c protease inhibitors |
EP1999108A1 (en) * | 2006-03-28 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
CL2007001011A1 (en) * | 2006-04-11 | 2008-05-16 | Arena Pharm Inc | METHOD FOR THE IDENTIFICATION OF GIP SECRETAGOGS, GASTRIC INHIBITOR POLYPEPTIDE; AND USE OF A PROTEIN G COUPLED RECEIVER TO CLASSIFY TEST COMPOUNDS AS GIP SECRETAGOGS. |
PE20071221A1 (en) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS |
KR20090004950A (en) | 2006-04-12 | 2009-01-12 | 프로비오드룩 아게 | Enzyme inhibitors |
CN101421238B (en) * | 2006-04-17 | 2013-01-09 | 住友化学株式会社 | Method for producing polycyclic proline derivative or acid addition salt thereof |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
EA030606B1 (en) | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Methods of preparing a medicament comprising polymorphs |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
MX2009000385A (en) | 2006-07-12 | 2009-04-06 | Univ Tennessee Res Foundation | Substituted acylanilides and methods of use thereof. |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
MX2009002282A (en) | 2006-09-07 | 2009-03-20 | Nycomed Gmbh | Combination treatment for diabetes mellitus. |
PE20080840A1 (en) * | 2006-09-13 | 2008-08-27 | Smithkline Beecham Corp | METHODS FOR ADMINISTERING LONG-LIVED HYPOGLYCEMIANT AGENTS |
KR20090088854A (en) * | 2006-09-13 | 2009-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | Administration of dipeptidyl peptidase inhibitors |
MX2009002893A (en) | 2006-09-18 | 2009-07-10 | Raptor Pharmaceutical Inc | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates. |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
US8217025B2 (en) * | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
WO2008091555A2 (en) | 2007-01-22 | 2008-07-31 | Gtx, Inc. | Nuclear receptor binding agents |
US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
CN101230058A (en) * | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | Bicycle aza alkyl derivative, preparation method and use in medicine thereof |
ES2354397T3 (en) | 2007-02-01 | 2011-03-14 | Takeda Pharmaceutical Company Limited | SOLID PREPARATION THAT INCLUDES ALOGLIPTINA AND PIOGLITAZONA. |
US20110020797A1 (en) * | 2007-02-09 | 2011-01-27 | Bristol-Myers Squibb Company | Methods For Identifying Patients With An Increased Likelihood Of Responding To DPP-IV Inhibitors |
US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
PE20090185A1 (en) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR |
ATE550319T1 (en) * | 2007-03-22 | 2012-04-15 | Kyorin Seiyaku Kk | METHOD FOR PRODUCING AN AMINOACETYLPYRROLIDINE CARBONITRILE DERIVATIVE |
US8927504B2 (en) | 2007-04-03 | 2015-01-06 | Mitsubishi Tanabe Pharma Corporation | Combined use of dipeptidyl peptidase 4 inhibitor and sweetener |
JP5667440B2 (en) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | Thiourea derivatives as glutaminyl cyclase inhibitors |
PE20090696A1 (en) * | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM |
EP2147008A2 (en) * | 2007-05-18 | 2010-01-27 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
CN101318925A (en) * | 2007-06-04 | 2008-12-10 | 上海恒瑞医药有限公司 | Pyrrolidine-tetratomic ring derivants, preparation method and medical uses thereof |
CA2963857A1 (en) | 2007-06-04 | 2008-12-11 | Ben-Gurion University Of The Negev Research And Development Authority | Tri-aryl compounds and compositions comprising the same |
AU2008268627A1 (en) * | 2007-06-22 | 2008-12-31 | Bristol-Myers Squibb Company | Tableted compositions containing atazanavir |
MX2009013461A (en) * | 2007-06-22 | 2010-01-15 | Bristol Myers Squibb Co | Tableted compositions containing atazanavir. |
US20100178340A1 (en) * | 2007-06-22 | 2010-07-15 | Bristol-Myers Squibb Company | Tableted compositions containing atazanavir |
SI2170292T1 (en) * | 2007-06-22 | 2014-05-30 | Bristol-Myers Squibb Holdings Ireland | Tableted compositions containing atazanavir |
CL2008002427A1 (en) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus. |
KR101610005B1 (en) * | 2007-08-17 | 2016-04-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Purin derivatives for use in the treatment of FAB-related diseases |
US20090076118A1 (en) * | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched saxagliptin |
GB2465132B (en) * | 2007-09-21 | 2012-06-06 | Lupin Ltd | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors |
CL2008003653A1 (en) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition. |
US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
WO2009140685A2 (en) * | 2008-05-16 | 2009-11-19 | Bristol-Myers Squibb Company | Methods for identifying subjects with an increased likelihood of responding to dpp-iv inhibitors |
PE20100156A1 (en) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | NAFLD TREATMENT |
WO2009155481A1 (en) | 2008-06-20 | 2009-12-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
BRPI0916997A2 (en) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | DPP-4 INHIBITOR AND ITS USE |
UY32030A (en) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN" |
EP2322499A4 (en) * | 2008-08-07 | 2011-12-21 | Kyorin Seiyaku Kk | Process for production of bicycloý2.2.2¨octylamine derivative |
JPWO2010018866A1 (en) * | 2008-08-14 | 2012-01-26 | 杏林製薬株式会社 | Stabilized pharmaceutical composition |
EA031225B1 (en) | 2008-08-15 | 2018-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Dpp-4 inhibitors for wound healing |
EP2344195A2 (en) | 2008-09-10 | 2011-07-20 | Boehringer Ingelheim International GmbH | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
WO2010043566A2 (en) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a glp-1 agonist |
DK2344519T3 (en) | 2008-11-07 | 2017-01-23 | Massachusetts Gen Hospital | C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1) |
EP2352722A4 (en) * | 2008-11-19 | 2012-07-25 | Auspex Pharmaceuticals Inc | Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv |
US20100144140A1 (en) * | 2008-12-10 | 2010-06-10 | Novellus Systems, Inc. | Methods for depositing tungsten films having low resistivity for gapfill applications |
DE102008062136B4 (en) | 2008-12-16 | 2012-05-03 | Kamamed Ug | Pharmaceutical composition based on peptide of camel milk |
BRPI0923121A2 (en) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Saline forms of organic compounds |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
US8706650B2 (en) * | 2009-01-14 | 2014-04-22 | Integral Analytics, Inc. | Optimization of microgrid energy use and distribution |
AR075204A1 (en) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | DPP-4 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL TO TREAT METABOLIC DISEASES IN PEDIATRIC PATIENTS, PARTICULARLY MELLITUS DIABETES TYPE 2 |
JP2012517977A (en) | 2009-02-13 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | An anti-diabetic drug comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other anti-diabetic drugs |
JP5685550B2 (en) | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pharmaceutical composition comprising SGLT2 inhibitor, DPP-IV inhibitor, and optionally antidiabetic agent, and use thereof |
WO2010111665A1 (en) * | 2009-03-27 | 2010-09-30 | Bristol-Myers Squibb Company | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors |
KR20120003906A (en) | 2009-03-27 | 2012-01-11 | 교린 세이야꾸 가부시키 가이샤 | Matrix-type sustained release preparation containing basic additive |
JP2012523235A (en) * | 2009-04-08 | 2012-10-04 | ブリストル−マイヤーズ スクイブ カンパニー | Genetically stable plasmids expressing PDH and FDH enzymes |
WO2010115974A1 (en) * | 2009-04-09 | 2010-10-14 | Sandoz Ag | Crystal forms of saxagliptin |
WO2010146597A1 (en) | 2009-06-18 | 2010-12-23 | Lupin Limited | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors |
AR077642A1 (en) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME |
MX2012002993A (en) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase. |
EP2308847B1 (en) | 2009-10-09 | 2014-04-02 | EMC microcollections GmbH | Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases |
CA2780941C (en) | 2009-11-13 | 2018-06-12 | Bristol-Myers Squibb Company | Immediate release tablet formulations |
ES2855146T3 (en) | 2009-11-13 | 2021-09-23 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
HUE040486T2 (en) | 2009-11-13 | 2019-03-28 | Astrazeneca Ab | Bilayer tablet formulations |
TWI562775B (en) | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
JP6026284B2 (en) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | Inhibitors of glutaminyl cyclase |
MX2012010470A (en) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5). |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
EP2368874A1 (en) | 2010-03-26 | 2011-09-28 | Sandoz AG | Racemisation of (R)-N-Boc-3-hydroxyadamant-1-yl glycine |
EP2769978A1 (en) * | 2010-04-05 | 2014-08-27 | Cadila Pharmaceuticals Limited | saxagliptin derivatives |
BR112012025592A2 (en) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | gpr119 receptor modulators and the treatment of disorders related thereto |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
EA201291169A1 (en) * | 2010-05-05 | 2013-04-30 | Ассия Кемикал Индастриз Лтд. | Intermediate compounds of saxagliptin, saxagliptin polymorphs and methods for their production |
JP6034781B2 (en) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination therapy |
EA201991014A1 (en) | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | DIABETES TREATMENT |
WO2012017029A1 (en) | 2010-08-06 | 2012-02-09 | Sandoz Ag | Novel salts of saxagrliptin with organic di-acids |
WO2012017028A1 (en) | 2010-08-06 | 2012-02-09 | Sandoz Ag | A novel crystalline compound comprising saxagliptin and phosphoric acid |
PT2611458T (en) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
EP2611770A1 (en) | 2010-09-03 | 2013-07-10 | Sandoz AG | Process for the reductive amination of -keto carboxylic acids |
MX2013002146A (en) | 2010-09-03 | 2013-04-03 | Astrazeneca Uk Ltd | Drug formulations using water soluble antioxidants. |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
US8410288B2 (en) | 2010-10-04 | 2013-04-02 | Teva Pharmaceutical Industries Ltd. | Polymorphs of Saxagliptin hydrochloride and processes for preparing them |
US9040481B2 (en) | 2010-11-02 | 2015-05-26 | The General Hospital Corporation | Methods for treating steatotic disease |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
TWI631963B (en) | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
UA110813C2 (en) | 2011-01-31 | 2016-02-25 | Каділа Хелткере Лімітед | Treatment of lipodystrophy |
EP2670397B1 (en) | 2011-02-01 | 2020-05-13 | Bristol-Myers Squibb Company | Pharmaceutical formulations including an amine compound |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP2729157B1 (en) | 2011-07-06 | 2019-01-16 | The General Hospital Corporation | A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment |
MX366629B (en) | 2011-07-15 | 2019-07-17 | Boehringer Ingelheim Int | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions. |
PT2750699E (en) | 2011-08-29 | 2015-11-03 | Sanofi Aventis Deutschland | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
EA201490556A1 (en) | 2011-09-07 | 2014-08-29 | Сановел Илач Санайи Ве Тиджарет Аноним Ширкети | COMPOSITIONS OF DPP-4 INHIBITOR |
ES2487271T3 (en) | 2011-10-06 | 2014-08-20 | Sanovel Ilac Sanayi Ve Ticaret A.S. | DPP-IV inhibitor solid dosage formulations |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
JPWO2013081100A1 (en) * | 2011-11-30 | 2015-04-27 | 積水メディカル株式会社 | Adamantyl hydantoin compounds |
US9115082B2 (en) | 2012-01-18 | 2015-08-25 | Catherine Yang | Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension |
US20150087686A1 (en) | 2012-04-25 | 2015-03-26 | Enantia, S.L. | Crystalline forms of saxagliptin |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
US8664443B2 (en) | 2012-05-23 | 2014-03-04 | Divi's Laboratories Ltd. | Process for the preparation of (1S, 3S, 5S)-2-[2(S)-2-amino-2-(3-hydroxy-1-adamantan-1-yl) acetyl]-2-azabicyclo [3.1.0] hexane-3-carbonitrile |
WO2013175297A1 (en) | 2012-05-24 | 2013-11-28 | Apotex Pharmachem India Pvt. Ltd | Salts of saxagliptin with organic acids |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2014006569A2 (en) | 2012-07-02 | 2014-01-09 | Ranbaxy Laboratories Limited | Saxagliptin salts |
CN103539724B (en) * | 2012-07-12 | 2017-09-26 | 博瑞生物医药(苏州)股份有限公司 | The novel crystal forms and purification process of BMS-477118 single stereoisomers |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
DK2872482T3 (en) | 2012-07-13 | 2020-09-21 | Oncternal Therapeutics Inc | A PROCEDURE FOR TREATING BREAST CANCER WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM) |
WO2014030051A1 (en) | 2012-08-23 | 2014-02-27 | Aurobindo Pharma Limited | Stable pharmaceutical compositions comprising saxagliptin |
WO2014057495A1 (en) | 2012-10-11 | 2014-04-17 | Lee Pharma Limited | A process for industrial preparation of [(s)-n-tert butoxycarbonyl-3-hydroxy]adamantylglycine |
TWI500613B (en) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | Novel heterocyclic compounds |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
NZ707859A (en) | 2012-11-20 | 2019-03-29 | Lexicon Pharmaceuticals Inc | Inhibitors of sodium glucose cotransporter 1 |
WO2014096983A1 (en) | 2012-12-21 | 2014-06-26 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
US20150250734A1 (en) | 2012-12-21 | 2015-09-10 | Wockhardt Limited | Stable pharmaceutical compositions of saxagliptin or salts thereof |
WO2014108830A1 (en) | 2013-01-10 | 2014-07-17 | Wockhardt Limited | A process for preparing pharmaceutically acceptable salt of saxagliptin |
ITMI20130132A1 (en) | 2013-01-30 | 2014-07-31 | Laboratorio Chimico Int Spa | PROCEDURE FOR THE PREPARATION OF INTERMEDIATES OF SAXAGLIPTINA SYNTHESIS AND NEW COMPOUNDS |
TWI780236B (en) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CN104059068B (en) * | 2013-03-20 | 2017-02-08 | 中国科学院上海药物研究所 | Beta-amino-carbonyl compound, preparation method, its pharmaceutical composition and application thereof |
CN104098481B (en) * | 2013-04-10 | 2016-05-11 | 浙江九洲药物科技有限公司 | A kind of preparation method of BMS-477118 intermediate |
EP2988736A1 (en) | 2013-04-22 | 2016-03-02 | Cadila Healthcare Limited | A novel composition for nonalcoholic fatty liver disease (nafld) |
WO2014193528A1 (en) * | 2013-04-29 | 2014-12-04 | Anovel Pharmaceuticals, Llc | Amorphous dosage forms and methods |
EP3004053B1 (en) | 2013-05-30 | 2021-03-24 | Cadila Healthcare Limited | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
JP6606491B2 (en) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | Ultra high purity agonist of guanylate cyclase C, method for producing and using the same |
TW201636015A (en) | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | Synergistic compositions |
IN2013MU02470A (en) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
EP2832723B1 (en) | 2013-07-29 | 2017-02-15 | Zentiva, a.s. | Stabilised amorphous forms of Saxagliptin |
US9416105B2 (en) | 2013-08-28 | 2016-08-16 | Amneal Pharmaceuticals Llc | Process for preparation of saxagliptin and its hydrochloride salt |
WO2015033357A2 (en) | 2013-09-06 | 2015-03-12 | Cadila Healthcare Limited | An improved process for the preparation of pyrrole derivatives |
ITMI20131677A1 (en) * | 2013-10-10 | 2015-04-11 | Olon Spa | PROCEDURE FOR THE PREPARATION OF SAXAGLIPTINA |
JP6657101B2 (en) | 2013-11-05 | 2020-03-04 | ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ | Compounds for the treatment of diabetes and disease complications resulting therefrom |
WO2015067223A1 (en) | 2013-11-06 | 2015-05-14 | Zentiva, K., S. | L-tartrate salt of (1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile and process for preparation thereof |
WO2015071889A1 (en) | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral compositions of saxagliptin |
WO2015071887A1 (en) | 2013-11-18 | 2015-05-21 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of saxagliptin |
WO2015087262A1 (en) | 2013-12-11 | 2015-06-18 | Ranbaxy Laboratories Limited | Process for the preparation of saxagliptin and its intermediates |
SG11201604706TA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
WO2015104311A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
CN112957455A (en) | 2014-01-09 | 2021-06-15 | 赛诺菲 | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
CZ2014177A3 (en) | 2014-03-24 | 2015-10-07 | Zentiva, K.S. | Process for preparing saxagliptin |
KR20160147007A (en) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | Carbonitrile derivatives as selective androgen receptor modulators |
WO2016016770A1 (en) | 2014-07-26 | 2016-02-04 | Wockhardt Limited | A novel modified release pharmaceutical composition of sitagliptin or pharmaceutically acceptable salt thereof |
GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
CN104557667A (en) * | 2014-12-12 | 2015-04-29 | 山东省药学科学院 | 2-cyano pyrrolidine compound, and preparation method and application thereof |
CN107206058A (en) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | Insulin glargine/lixisenatide fixed ratio preparaton |
EA201791982A1 (en) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | METHODS FOR TREATING A NON-ALCOHOLIC FAT LIVER DISEASE AND / OR LIPODYSTROPHY |
TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
CN105037245B (en) * | 2015-08-03 | 2017-04-12 | 沧州那瑞化学科技有限公司 | Saxagliptin midbody preparing method |
US10385017B2 (en) | 2015-10-14 | 2019-08-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
KR101715682B1 (en) | 2015-10-29 | 2017-03-13 | 경동제약 주식회사 | Novel intermediates for preparing saxagliptin, preparing methods thereof and preparing methods of saxagliptin using the same |
JP2019517542A (en) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination of linagliptin and metformin |
US20180243263A1 (en) | 2016-12-09 | 2018-08-30 | Cadila Healthcare Ltd. | Treatment for primary biliary cholangitis |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
CA3058806A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | Ppar.gamma. agonist for treatment of progressive supranuclear palsy |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
CN109970620B (en) * | 2017-12-27 | 2022-07-12 | 江苏威凯尔医药科技有限公司 | Method for preparing saxagliptin intermediate |
CA3103425A1 (en) * | 2018-06-14 | 2019-12-19 | Robert Peter PRYBOLSKY | Methods for lowering blood sugar with a dipeptidyl peptidase-4 inhibitor pharmaceutical composition |
BR112021000139A2 (en) | 2018-07-19 | 2021-04-06 | Astrazeneca Ab | METHODS OF TREATMENT OF HFPEF USING DAPAGLIFLOZINE AND COMPOSITIONS UNDERSTANDING THE SAME |
BR112021004839A2 (en) | 2018-09-26 | 2021-06-08 | Lexicon Pharmaceuticals, Inc. | crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2s,3r) ,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenyl)butanamide and methods of its synthesis |
RU2712097C1 (en) * | 2018-09-28 | 2020-01-24 | Общество с ограниченной ответственностью "Необиотек" | Dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes mellitus, compounds (versions) |
RU2727898C1 (en) * | 2020-02-25 | 2020-07-24 | Общество с ограниченной ответственностью «Необиотек» | Pharmaceutical composition based on an active substance, an inhibitor of dipeptidyl peptidase-4, for preventing the development and treatment of type 2 diabetes mellitus |
US20220023252A1 (en) | 2020-07-27 | 2022-01-27 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
CN113666846B (en) * | 2021-08-31 | 2023-06-27 | 济南立德医药技术有限公司 | Synthesis method of saxagliptin intermediate |
WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0007652A1 (en) * | 1978-06-27 | 1980-02-06 | Shell Internationale Researchmaatschappij B.V. | Derivatives of 3-azabicyclo(3.1.0)hexane and a process for their preparation |
US4379785A (en) * | 1979-12-19 | 1983-04-12 | Hoechst Aktiengesellschaft | Heterocyclic substituted sulfonyl ureas, and their use |
DE3324263A1 (en) * | 1983-07-06 | 1985-01-17 | Hoechst Ag, 6230 Frankfurt | DERIVATIVES OF 2-AZABICYCLO (3.1.0) HEXAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF, AND 2-AZABICYCLO (3.1.0) HEXANE DERIVATIVES AS INTERMEDIATE PRODUCTS AND PROCESS PRODUCTS |
EP0219782A2 (en) * | 1985-10-15 | 1987-04-29 | Hoechst Aktiengesellschaft | Use of angiotensin-converting enzyme inhibitors in the treatment of atherosclerosis, thrombosis and peripheral vascular disease |
DE3926606A1 (en) * | 1989-08-11 | 1991-02-14 | Hoechst Ag | METHOD FOR THE TREATMENT OF CARDIALS AND VASCULAR HYPERTROPHY AND HYPERPLASIA |
WO1999026659A1 (en) * | 1997-11-21 | 1999-06-03 | Pfizer Products Inc. | Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor |
WO1999047545A2 (en) * | 1998-03-19 | 1999-09-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
WO1999067279A1 (en) * | 1998-06-24 | 1999-12-29 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Compounds of unstable dipeptidyl peptidase iv inhibitors |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3325478A (en) * | 1964-11-17 | 1967-06-13 | Du Pont | alpha-amino-1-adamantylmethyl penicillins |
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
JPS5246949B2 (en) | 1973-10-19 | 1977-11-29 | ||
YU36151B (en) * | 1974-05-16 | 1982-02-25 | Pliva Zagreb | Process for preparing alpha-amino-2-adamantyl acetic acid |
JPS5612114B2 (en) | 1974-06-07 | 1981-03-18 | ||
US4183857A (en) | 1978-07-06 | 1980-01-15 | Shell Oil Company | 3-Benzyl-3-azabicyclo(3.1.0)hexane-2,4-dione |
NO154918C (en) | 1977-08-27 | 1987-01-14 | Bayer Ag | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE. |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
MX7065E (en) | 1980-06-06 | 1987-04-10 | Sankyo Co | A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
JPS6051189A (en) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | Thiazolidine derivative and its preparation |
DE3543999A1 (en) | 1985-12-13 | 1987-06-19 | Bayer Ag | HIGH PURITY ACARBOSE |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
JP2569746B2 (en) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | Quinoline mevalonolactones |
US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
NO177005C (en) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogous process for the preparation of substituted pyridines, as well as intermediates for use in the preparation |
FI94339C (en) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
US5462928A (en) | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (en) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | Pyrimidine derivatives |
DK0610317T3 (en) | 1991-10-22 | 2001-02-19 | New England Medical Center Inc | Inhibitors of dipeptidyl aminopeptidase type IV |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
DK36392D0 (en) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | USE OF CHEMICAL COMPOUND |
US5447954A (en) | 1992-05-05 | 1995-09-05 | Smithkline Beecham P.L.C. | Phenylderivate as inhibitors of ATP citrate lyase |
US5470845A (en) | 1992-10-28 | 1995-11-28 | Bristol-Myers Squibb Company | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
ATE178794T1 (en) | 1993-01-19 | 1999-04-15 | Warner Lambert Co | STABILIZED ORAL COMPOSITION CONTAINING THE COMPOUND CI-981 AND METHOD |
US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5561146A (en) | 1994-06-10 | 1996-10-01 | Bristol-Myers Squibb Company | Modified guanidino and amidino thrombin inhibitors |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
US6107329A (en) | 1995-06-06 | 2000-08-22 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
US6297269B1 (en) | 1995-06-06 | 2001-10-02 | Pfizer Inc. | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
ES2191117T3 (en) | 1995-10-25 | 2003-09-01 | Degussa | HERBICIDE SULFONAMIDS. |
WO1997021993A2 (en) | 1995-12-13 | 1997-06-19 | The Regents Of The University Of California | Nuclear receptor ligands and ligand binding domains |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
DE122010000020I1 (en) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Method for lowering the blood glucose level in mammals |
US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
US5952322A (en) | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
DE19742601A1 (en) * | 1997-09-26 | 1999-04-29 | Siemens Ag | Method and device for generating frames around video images |
EP1052994A2 (en) | 1998-02-02 | 2000-11-22 | Trustees Of Tufts College | Use of dipeptidylpetidase inhibitors to regulate glucose metabolism |
IL136588A0 (en) | 1998-02-27 | 2001-06-14 | Pfizer Prod Inc | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia |
EP0978279A1 (en) | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
EP1104293A1 (en) | 1998-08-21 | 2001-06-06 | Point Therapeutics, Inc. | Regulation of substrate activity |
CO5150173A1 (en) | 1998-12-10 | 2002-04-29 | Novartis Ag | COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION |
WO2000038722A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS |
EP1156803A4 (en) | 1999-02-09 | 2004-03-17 | Bristol Myers Squibb Co | LACTAM INHIBITORS OF FXa AND METHOD |
WO2000047206A1 (en) | 1999-02-12 | 2000-08-17 | Novo Nordisk A/S | Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation |
AU3960400A (en) | 1999-03-05 | 2000-09-28 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
GB9906714D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for improving fertility |
GB9906715D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for promoting growth |
PT1041068E (en) | 1999-04-01 | 2004-07-30 | Pfizer Prod Inc | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DIABETIC COMPLICATIONS |
JP4121215B2 (en) | 1999-05-17 | 2008-07-23 | 財団法人微生物化学研究会 | Sulfostin analog, and method for producing sulfostine and its analog |
US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
CA2436774A1 (en) | 2001-01-30 | 2002-08-08 | R. Michael Lawrence | Sulfonamide lactam inhibitors of factor xa |
DE10132375A1 (en) | 2001-07-07 | 2003-01-16 | Trench Germany Gmbh | Method and device for producing an electrical plastic insulator |
CN101023052A (en) | 2004-09-17 | 2007-08-22 | 雅宝公司 | Synthesis process for 2-(3-hydroxy-1-adamantyl)-2-oxoacetic acid |
US7205432B2 (en) | 2005-05-31 | 2007-04-17 | Kemfine Oy | Process for the preparation of adamantane derivatives |
EP2314574A1 (en) | 2005-06-17 | 2011-04-27 | Apogee Biothechnology Corporation | Sphingosine kinase inhibitors |
-
2001
- 2001-02-16 US US09/788,173 patent/US6395767B2/en not_active Ceased
- 2001-02-28 EG EG2001020212A patent/EG25854A/en active
- 2001-03-05 PT PT01918383T patent/PT1261586E/en unknown
- 2001-03-05 CZ CZ2015493A patent/CZ307821B6/cs not_active IP Right Cessation
- 2001-03-05 MX MXPA02008837A patent/MXPA02008837A/en active IP Right Grant
- 2001-03-05 BR BRPI0109115A patent/BRPI0109115B8/en not_active IP Right Cessation
- 2001-03-05 DE DE60134122T patent/DE60134122D1/en not_active Expired - Lifetime
- 2001-03-05 CA CA2402894A patent/CA2402894C/en not_active Expired - Lifetime
- 2001-03-05 SG SG200405783-2A patent/SG152030A1/en unknown
- 2001-03-05 WO PCT/US2001/007151 patent/WO2001068603A2/en active Application Filing
- 2001-03-05 CN CNB018063152A patent/CN1213028C/en not_active Expired - Lifetime
- 2001-03-05 DE DE122010000008C patent/DE122010000008I1/en active Pending
- 2001-03-05 JP JP2001567699A patent/JP4460205B2/en not_active Expired - Lifetime
- 2001-03-05 EP EP15186007.9A patent/EP2995615B1/en not_active Expired - Lifetime
- 2001-03-05 ES ES15186007T patent/ES2768961T3/en not_active Expired - Lifetime
- 2001-03-05 CZ CZ2014-33A patent/CZ307784B6/en not_active IP Right Cessation
- 2001-03-05 ES ES05005368.5T patent/ES2456667T3/en not_active Expired - Lifetime
- 2001-03-05 TW TW095105942A patent/TW200624420A/en unknown
- 2001-03-05 IL IL15137201A patent/IL151372A0/en unknown
- 2001-03-05 TW TW090104965A patent/TWI258468B/en active
- 2001-03-05 ES ES01918383T patent/ES2305062T3/en not_active Expired - Lifetime
- 2001-03-05 HU HU1200546A patent/HU230380B1/en unknown
- 2001-03-05 AT AT01918383T patent/ATE396176T1/en active
- 2001-03-05 EP EP01918383A patent/EP1261586B1/en not_active Expired - Lifetime
- 2001-03-05 KR KR1020067004515A patent/KR100758407B1/en active IP Right Grant
- 2001-03-05 EP EP05005368.5A patent/EP1559710B1/en not_active Expired - Lifetime
- 2001-03-05 DK DK01918383T patent/DK1261586T3/en active
- 2001-03-05 ES ES10178907.1T patent/ES2553573T3/en not_active Expired - Lifetime
- 2001-03-05 RU RU2002125491/04A patent/RU2286986C2/en active Protection Beyond IP Right Term
- 2001-03-05 NZ NZ520821A patent/NZ520821A/en not_active IP Right Cessation
- 2001-03-05 HU HU1200545A patent/HU230347B1/en unknown
- 2001-03-05 CN CNA2005100785188A patent/CN1698601A/en active Pending
- 2001-03-05 AU AU2001245466A patent/AU2001245466B2/en active Active
- 2001-03-05 EP EP10178907.1A patent/EP2272825B1/en not_active Expired - Lifetime
- 2001-03-05 PL PL365520A patent/PL207041B1/en unknown
- 2001-03-05 KR KR1020027011806A patent/KR100754089B1/en active IP Right Review Request
- 2001-03-05 HU HU0302792A patent/HU228110B1/en active Protection Beyond IP Right Term
- 2001-03-05 AU AU4546601A patent/AU4546601A/en active Pending
- 2001-03-05 CZ CZ2002-2974A patent/CZ304355B6/en unknown
- 2001-03-08 CO CO01018857A patent/CO5280198A1/en active IP Right Grant
- 2001-03-09 AR ARP010101122A patent/AR027634A1/en active IP Right Grant
- 2001-03-09 MY MYPI20011103A patent/MY124512A/en unknown
- 2001-03-12 UY UY26613A patent/UY26613A1/en not_active IP Right Cessation
- 2001-06-12 PE PE2001000554A patent/PE20020771A1/en not_active Application Discontinuation
-
2002
- 2002-08-21 IL IL151372A patent/IL151372A/en active Protection Beyond IP Right Term
- 2002-08-26 ZA ZA200206816A patent/ZA200206816B/en unknown
- 2002-09-09 NO NO20024295A patent/NO324227B1/en not_active IP Right Cessation
-
2003
- 2003-02-14 HK HK03101079.9A patent/HK1049330B/en unknown
-
2006
- 2006-07-23 IL IL177019A patent/IL177019A/en active IP Right Grant
- 2006-07-23 IL IL177018A patent/IL177018A0/en active IP Right Grant
-
2008
- 2008-08-20 CY CY20081100885T patent/CY1108273T1/en unknown
-
2010
- 2010-01-14 JP JP2010006181A patent/JP5427047B2/en not_active Expired - Lifetime
- 2010-02-11 BE BE2010C008C patent/BE2010C008I2/fr unknown
- 2010-02-17 NL NL300436C patent/NL300436I1/en unknown
- 2010-02-17 LU LU91650C patent/LU91650I2/en unknown
- 2010-02-22 FR FR10C0010C patent/FR10C0010I2/en active Active
- 2010-03-16 NO NO2010006C patent/NO2010006I2/en unknown
- 2010-03-30 CY CY2010005C patent/CY2010005I1/en unknown
-
2011
- 2011-06-24 HK HK11106580.0A patent/HK1152516A1/en not_active IP Right Cessation
- 2011-12-01 US US13/308,658 patent/USRE44186E1/en not_active Expired - Lifetime
-
2012
- 2012-04-18 BE BE2012C016C patent/BE2012C016I2/fr unknown
- 2012-04-23 DE DE201212000023 patent/DE122012000023I1/en active Pending
- 2012-04-24 CY CY2012009C patent/CY2012009I2/en unknown
- 2012-04-25 LU LU91985C patent/LU91985I2/en unknown
- 2012-05-21 NO NO2012009C patent/NO2012009I2/en unknown
- 2012-11-30 JP JP2012263345A patent/JP2013040219A/en active Pending
- 2012-12-14 HU HUS1200030C patent/HUS1200030I1/en unknown
- 2012-12-14 HU HUS1200031C patent/HUS1200031I1/en unknown
-
2013
- 2013-03-20 UY UY0001034691A patent/UY34691A/en unknown
- 2013-12-02 JP JP2013249334A patent/JP5953292B2/en not_active Expired - Lifetime
-
2015
- 2015-04-28 JP JP2015092196A patent/JP5951843B2/en not_active Expired - Lifetime
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0007652A1 (en) * | 1978-06-27 | 1980-02-06 | Shell Internationale Researchmaatschappij B.V. | Derivatives of 3-azabicyclo(3.1.0)hexane and a process for their preparation |
US4254057A (en) * | 1978-06-27 | 1981-03-03 | Shell Oil Company | 2-Aminomethylcyclopropyl-1,1-dialkylacetals |
US4379785A (en) * | 1979-12-19 | 1983-04-12 | Hoechst Aktiengesellschaft | Heterocyclic substituted sulfonyl ureas, and their use |
DE3324263A1 (en) * | 1983-07-06 | 1985-01-17 | Hoechst Ag, 6230 Frankfurt | DERIVATIVES OF 2-AZABICYCLO (3.1.0) HEXAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF, AND 2-AZABICYCLO (3.1.0) HEXANE DERIVATIVES AS INTERMEDIATE PRODUCTS AND PROCESS PRODUCTS |
EP0219782A2 (en) * | 1985-10-15 | 1987-04-29 | Hoechst Aktiengesellschaft | Use of angiotensin-converting enzyme inhibitors in the treatment of atherosclerosis, thrombosis and peripheral vascular disease |
DE3926606A1 (en) * | 1989-08-11 | 1991-02-14 | Hoechst Ag | METHOD FOR THE TREATMENT OF CARDIALS AND VASCULAR HYPERTROPHY AND HYPERPLASIA |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
WO1999026659A1 (en) * | 1997-11-21 | 1999-06-03 | Pfizer Products Inc. | Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor |
US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
WO1999047545A2 (en) * | 1998-03-19 | 1999-09-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
WO1999067279A1 (en) * | 1998-06-24 | 1999-12-29 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Compounds of unstable dipeptidyl peptidase iv inhibitors |
Non-Patent Citations (3)
Title |
---|
HANESSIAN S ET AL: "Probing the Importance of Spacial and Conformational Domains in Captopril Analogs for Angiotensin Converting Enzyme Activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 16, 18 August 1998 (1998-08-18), pages 2123 - 2128, XP004137231, ISSN: 0960-894X * |
SAGNARD I ET AL: "Enantioselective Synthesis of Cyclopropane alpha-Amino Acids: Synthesis of N-Boc-cis-(2S,3R,4S)-3,4-Methanoproline and N-Boc-(2S,3R,4S)-3,4-Methanoglutamic Acid", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 36, no. 18, 1 May 1995 (1995-05-01), pages 3149 - 3152, XP004028212, ISSN: 0040-4039 * |
TVEREZOVSKY V V ET AL: "Synthesis of (2S, 3R, 4S)-3,4-Methanoproline and Analogues by Cyclopropylidene Insertion", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 53, no. 43, 27 October 1997 (1997-10-27), pages 14773 - 14792, XP004106307, ISSN: 0040-4020 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US9321791B2 (en) | 2002-08-21 | 2016-04-26 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7897633B2 (en) | 2004-02-05 | 2011-03-01 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US8906901B2 (en) | 2005-09-14 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US9150501B2 (en) | 2007-09-11 | 2015-10-06 | Gtx, Inc. | Solid forms of selective androgen receptor modulators |
US9415016B2 (en) | 2008-04-03 | 2016-08-16 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US8883714B2 (en) | 2008-04-07 | 2014-11-11 | Arena Pharmaceuticals, Inc. | Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001068603A3 (en) | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use | |
HU0401423D0 (en) | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method | |
WO2000059506A8 (en) | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | |
MXPA03011981A (en) | 3-fluoro-pyrrolidines as antidiabetic agents. | |
GB0010188D0 (en) | Inhibitors of dipeptidyl peptidase IV | |
MXPA04003829A (en) | Inhibitors of dipeptidyl peptidase iv. | |
WO2003044015A3 (en) | Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors | |
WO2003000181A3 (en) | Dipeptidyl peptidase inhibitors for the treatment of diabetes | |
WO2003059378A3 (en) | Combined use of a glp-1 compound and another drug for treating dyslipidemia | |
GEP20033028B (en) | Heterocyclic Compounds as Inhibitors of Rotamase Enzymes, Method for Their Production, Pharmaceutical Composition Containing Them and Use Thereof | |
EP0633254A4 (en) | Novel isoxazole derivative and salt thereof. | |
EP0640586A4 (en) | Stilbene derivative and stilbene analog derivative, and use thereof. | |
GEP20053626B (en) | Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof | |
WO2002030867A3 (en) | Drugs for diabetes | |
AU2002246317A1 (en) | Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof | |
WO2002004412A3 (en) | Tyrosine derivatives as phosphatase inhibitors | |
ES8506663A1 (en) | Aldose reductase inhibiting 5-(2-alkoxyphenyl)thiazolidinediones. | |
TH51866B (en) | Dipeptidylpeptidase IV type of cyclopropyl-fusion perrolidine type inhibitor and method of operation. | |
ECSP003408A (en) | Biphenyl aPz inhibitors containing heterocyclic compounds and method | |
TH14842EX (en) | HIV protease inhibitors useful in the treatment of AIDS | |
TH14842A (en) | HIV protease inhibitors useful in the treatment of AIDS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 520821 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 151372 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/01154/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/06816 Country of ref document: ZA Ref document number: 200206816 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-2974 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2001 567699 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018063152 Country of ref document: CN Ref document number: 2001245466 Country of ref document: AU Ref document number: 1020027011806 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/008837 Country of ref document: MX Ref document number: 2402894 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002125491 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001918383 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001918383 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-2974 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027011806 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 520821 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 520821 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001245466 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 177018 Country of ref document: IL Ref document number: 177019 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2014-33 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2015-493 Country of ref document: CZ |